| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Center of Internal Medicine, Medical Department I, Division of Endocrinology, University Hospital (H.D., T.S., J.B., J.H. K.H.U., K.B.), D-60590 Frankfurt am Main; and the Paul Ehrlich Institut (R.R.T., R.K.), D-63225 Langen, Germany; and the Diabetes Research Center, Vrije Universiteit Brussels (B.V.d.A., I.W.), B-1090 Brussels, Belgium
Address all correspondence and requests for reprints to: Dr. Klaus Badenhoop, Center of Internal Medicine, Medical Department I, Division of Endocrinology, University Hospital, Theodor Stern Kai 7, D-60590 Frankfurt am Main, Germany. E-mail: badenhoop{at}em.uni-frankfurt.de
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The human endogenous retrovirus K (HERV-K) family is present in 3050 full-length copies (11), whereas about 10,000 solitary long terminal repeats (LTRs) exist per haploid human genome (12). The evolutionary development of the MHC was accompanied by insertions of endogenous retro-viral DNA elements such as LTRs at several sites (9), which contribute to the heterogeneity of MHC haplotypes. Two LTRs with more than 90% sequence homology to the HERV-K LTR had earlier been described in the vicinity of HLA DQ (13). We recently demonstrated that the presence of one of these LTRs (DQ-LTR3) was significantly associated with type 1 diabetes (14) as well as with rheumatoid arthritis (15).
The aims of this study were to characterize the linkage of DQ-LTR3 to HLA DR-DQ haplotypes and to investigate whether DQ-LTR3 is an additional and independent genetic marker in type 1 diabetes.
| Experimental Subjects |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
HLA DQ, DR, and DQ-LTR3 genotyping
Genomic DNA was isolated from whole ethylenediamine tetraacetate blood samples and subjected to PCR analyses that always included a negative control standard with all reagents but genomic DNA. HLA DQA1 and DQB1 alleles were defined by sequence-specific primer or allele-specific oligonucleotide analysis based on the recent WHO HLA nomenclature (18, 19). Additionally, HLA DRB1*04 subtypes were studied in all DQA1*03- and DQB1*03-positive individuals (20). In this way we could distinguish 11 HLA DRB1*04 alleles.
The presence or absence of DQ-LTR3 was defined by a nested PCR. For DQ-LTR3, external primers were used (5'-AATGCTGATTAGAAGTAGCTCTG-3' and 5'-ACAAGGACATCTCCTGATCAG-3') to generate a 1285-bp fragment (49256210, clone HSE1448, GenBank Z80898) in the presence of the DQ-LTR3 or a 310-bp fragment in the absence. All amplifications were performed on a Multicycler PTC 200 (Biozym, Hess Oldendorf, Germany). All external fragments were amplified using the Expand High Fidelity PCR system (Boehringer Mannheim, Mannheim, Germany) in the following reaction: 250 ng genomic DNA, 8 mmol/L deoxy-NTPs, 20 pmol of each primer, 1.5 mmol/L MgCl2, and 1.5 U of polymerase mix. For DQ-LTR3, 30 cycles (94 C for 1 min, 61 C for 1 min, and 72 C for 75 s) after 4-min initial denaturation and with a final extension for 4 min were applied. A 1008-bp internal fragment of DQ-LTR3 was amplified only in the presence of DQ-LTR3 with the following primers: 5'-GGTGGAGCAACAGCCCACCCGGG AAGT-3' and 5'-CCCCTTGTGACTTCTGTGGGGAAAAGC-3' (50566084, clone 1448, GenBank Z80898). The PCR reactions were carried out as for the external fragments but using Taq polymerase (Promega Corp., Madison, WI), 10 mmol/L Tris-HCl, 50 mmol/L KCl, and 1.5 mmol/L MgCl2 in a final volume of 25 µL under the following conditions: initial denaturation (94 C) for 4 min and 30 cycles (94 C for 1 min, 62 C for 1 min, and 72 C for 1 min) and a final extension for 4 min.
To confirm our results, DQ-LTR3-positive and -negative PCR fragments were purified on agarose gels and cloned into the TA cloning vector pGem-T easy (Promega Corp.). Inserts devoid of LTR sequences were fully sequenced, and inserts containing LTR elements were partially sequenced using a cycle-sequencing protocol employing SP6 and T7 primers with Thermo Sequenase and Taq DyeDeoxy terminators on a 373A DNA Sequencing System according to the instructions of the manufacturer (Amersham, Aylesbury, UK). Primers were commercially purchased from Eurogentec (Seraing, Belgium) and Roth (Karlsruhe, Germany).
Segregation analysis
Genotypes of patients, their parents, and siblings were compared to define haplotypes. No recombination was observed, and all families displayed segregation patterns of Mendelian inheritance. Alleles that were found in patients were classified as transmitted, whereas those parental alleles not observed in patients were classified as not transmitted. Studying 246 nuclear families thus resulted in the analysis of 984 haplotypes. Segregation of DQ-LTR3 in families allowed us to assign their linkage to HLA DQA1 and DQB1 alleles on haplotypes.
Statistics
To analyze our data we performed different types of statistics.
First, the combined transmissions of selected haplotypes, either
DQ-LTR3 positive or negative, were analyzed by a transmission
distortion test. The observed transmissions were compared to the random
expected transmissions of 50% by the
2 test (21) (Table 1
). Only transmissions from heterozygous
parents were counted, and statistical significance was defined as
P < 0.05 (1 df) with Yates correction and Fishers
exact test where appropriate. Additionally, we compared the
distribution of DQ-LTR3 on transmitted with that on not transmitted DQ
haplotypes by
2 test (see Table 2
). Third, the positive and negative
predictive values (PPV and NPV) as well as the haplotype relative risk
(HRR) were calculated (see Table 3
).
These latter comparisons included all transmissions, also from
homozygous parents (22). The formats for the calculations of PPV and
NPV values are shown in Table 3
. In the analysis of DQ-LTR3
presence/absence, we tested the a priori hypothesis that the
frequency of DQ-LTR3-positive haplotypes differed between selected
haplotypes (e.g. HLA DQA1*03 and DQB1*0302) known to confer
strong susceptibility to type 1 diabetes. Thus, P values
generated from this comparison (DQ-LTR3 ± on these haplotypes)
were not corrected.
|
|
|
| Results |
|---|
|
|
|---|
Table 1
displays the combined transmission of DQ-LTR3 with
selected DQA1, DQB1, and DRB1*04 alleles from heterozygous parents in
492 transmitted and 492 nontransmitted haplotypes derived from 246
German and Belgian families with an type 1 diabetic patient as
offspring. As expected, 78% of all DQB1*0302-positive parental
haplotypes (P < 10-6) were transmitted to
patients. Subdividing DQB1*0302 haplotypes into DQ-LTR3 positive and
negative, this transmission rate increased to 82% for all
DQ-LTR3-positive haplotypes (P < 10-6),
whereas only 29% of all DQB1*0302 DQ-LTR3-negative haplotypes were
transmitted. The transmission of HLA DQA1*0301- and DQB1*0301-positive
haplotypes was reduced independently of that of DQ-LTR3 (40% for
DQLTR3-positive and 35% for DQ-LTR3-negative haplotypes). We observed
the highest transmission rate for the extended DRB1*0401- and DQB1*0302
DQ-LTR3-positive haplotype (84%; P <
10-6), in contrast to only one of six DRB1*0401-,
DQB1*0302-, and DQ-LTR3-negative haplotypes (17%).
Also, the DQA1*0501 DQB1*0201 haplotype was preferentially transmitted to patients (78%; P < 10-6). Comparing these DQB1*0201 haplotypes, the transmission rate was 80% (P < 10-6) for all DQLTR3-negative haplotypes, whereas it was less frequent (36%) for all DQB1*0201 DQ-LTR3-positive haplotypes. HLA DQA1*0501 DQB1*0301 was less often transmitted to patients (16%; P < 2 x 10-6) for both DQ-LTR3-positive (18%) and DQ-LTR3-negative haplotypes (16%). There were no significant differences for DQ-LTR3 frequencies among haplotypes with other HLA DQA1/B1 alleles.
To address the question of whether the frequencies of DQ-LTR3
differed significantly on DQB1*0302- or DQB1*0201-transmitted compared
to nontransmitted haplotypes, we performed a
2 test (see
Table 2
). DQ-LTR3 was significantly more frequent on
DQA1*0301-transmitted haplotypes but was significantly less so on
DQA1*0501-transmitted haplotypes (P < 2 x
10-6 and P < 10-6,
respectively). Also, the extended haplotypes DQA1*0301, DQB1*0302
(P < 0.004), DRB1*0401, DQB1*0302 (P
< 9 x 10-4), as well as DQA1*0501, DQB1*0201
(P < 0.003) differed significantly when transmitted
haplotypes were compared to nontransmitted haplotypes for DQLTR3. The
DQ-LTR3 distribution on the protective DQA1*0301 DQB1*0301 and
DQA1*0501 DQB1*0301 haplotypes was not different.
Calculation of the PPV and NPV as well as the HRR of selected haplotypes
We also tested whether the retroviral element would qualify as an
additional risk marker. Table 3
summarizes the PPV and NPV as well as
the HRR. When this analysis was performed, we compared haplotypes
positive for a marker combination against the remaining haplotypes
(either transmitted or nontransmitted). Therefore, the numbers of
haplotypes differ in Table 3
from those in Table 1
, where only
transmissions from heterozygous parents were counted. High risk
DQB1*0302 or DQB1*0201 haplotypes subdivided into DQ-LTR3-positive or
-negative haplotypes differed in the PPV. The PPV of DQA1*03
DQ-LTR3-positive haplotypes was 0.74, whereas it was 0.39 on
DQ-LTR3-negative haplotypes. Also, DQB1*0302 as well as the extended
DRB1*0401-, DQB1*0302-, and DQ-LTR3-positive haplotypes showed a higher
PPV (0.78 and 0.82) compared to DQ-LTR3-negative haplotypes (0.29 and
0.17). The absence of DQ-LTR3 on DQA1*0501 haplotypes was associated
with a higher PPV (0.62), whereas it was lower in its presence (0.23).
Similarly, the PPV for DQB1*0201 haplotypes without DQ-LTR3 was 0.75,
and that for DQB1*0201 DQ-LTR3-positive haplotypes was 0.36. The PPV do
not substantially vary when protective DQA1*0301, DQB1*0301 or
DQA1*0501, DQB1*0301 haplotypes were analyzed for DQ-LTR3.
The HRR was 4.5 for DQB1*0302-positive haplotype, 4.9 for DQB1*0302 DQ-LTR3-positive haplotype, and 5.6 for the extended DRB1*0401, DQB1*0302 DQ-LTR3-positive haplotype. The HRR of DQB1*0201 DQ-LTR3-negative haplotype was 4.2. In contrast, DQB1*0302 DQ-LTR3-negative and DQB1*0201 DQ-LTR3-positive haplotypes conferred a HRR below 1.
Sequence analysis of DQ-LTR3 flanking sites
Furthermore, we sequenced the flanking chromosomal regions encompassing the LTR or, in their absence, their corresponding empty sites in selected DQ-LTR3+/+, DQ-LTR3+/-, and DQ-LTR3-/- individuals and confirmed our results obtained by DQ-LTR3 PCR (data not shown). No variation within the DQ-LTR3 sequences was found.
| Discussion |
|---|
|
|
|---|
Conversely, the HLA DQA1*0501, DQB1*0201 haplotypes transmitted to patients were rarely DQ-LTR3 positive. Therefore, the absence of DQLTR3 on HLA DQA1*0501 DQB1*0201 haplotypes marks a more susceptible haplotype than that defined by its DQ alleles alone.
Why some HLA haplotypes appear to have integrated the DQ-LTR3 more frequently than others is unclear at present. This integration must have occurred late in the evolution of the MHC (23). Our observations are therefore consistent with recent findings that the HLA DQB1 locus reveals the highest level of sequence variation found in the human genome to date and that most of the major insertions/deletions are of retroviral origin (24). Thus, haplotype- specific variation, as seen in our family study, extends beyond the exons and transcriptional units. Also, HLA DRB1 exons are surrounded by similar polymorphic microsatellites even in distant populations (25). Thus, exon variation has evolved in parallel with intron polymorphism.
The genetic risk of DR3 and DR4 haplotypes was recently fine mapped with HLA-B alleles and microsatellite markers (6, 10). In our study the presence of DQ-LTR3 clearly distinguishes HLA DR4, DQB1*0302 with regard to IDDM susceptibility, in contrast to the absence of LTR on transmitted DQB1*0201 haplotypes. We also observe a strong difference in the PPV of high risk DQB1*0302 or DQB1*0201 haplotypes when subdivided into DQ-LTR3-positive and -negative groups. As the presence or absence of DQ-LTR3 only splits susceptible haplotypes, protection seems to be dominant, as seen in HLA class II exon variants (26). It is conceivable that the presence of retroelements might correlate with the high degree of diversity that distinguishes the MHC from other regions. Thus, these elements might have helped to shape the immunogenetic repertoire in accordance with the infectious environment during evolution. The documented retroelements within the MHC are not known to have interfered with gene function. Nevertheless, they may affect gene transcription by direct, indirect, or tissue-specific regulation of DQB1, as has been reported for other loci (24, 27, 28, 29).
The significantly different transmission of DQ-LTR3 on HLA DRB1*0401, DQB1*0302 suggests that this LTR represents an additional susceptibility marker. In contrast, the absence of DQ-LTR3 enhances the risk on the other predisposing HLA DQA1*0501, DQB1*0201 haplotype.
This is the first report of heterogeneity within the DRB1*0401 DQB1*0302 haplotype, suggesting that the contribution of allelic variation of exon 2 of HLA DRB1, DQA1, and DQB1 genes cannot completely explain the association of this haplotype with type 1 diabetes. Thus, the DQ-LTR3 marks a DR4 haplotype that presumably contains a genetic factor with a strong influence on susceptibility to type 1 diabetes.
| Acknowledgments |
|---|
Received November 6, 1998.
Revised January 7, 1998.
Accepted January 20, 1998.
| References |
|---|
|
|
|---|
gene polymorphisms in type 1 (insulin-dependent) diabetes
mellitus. Diabetologia. 32:445448.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
G. Gambelunghe, I. Kockum, V. Bini, G. D. Giorgi, F. Celi, C. Betterle, R. Giordano, R. Libe, A. Falorni, and on behalf of the Umbria Type 1 Diabetes Registry a Retrovirus-Like Long-Terminal Repeat DQ-LTR13 and Genetic Susceptibility to Type 1 Diabetes and Autoimmune Addison's Disease Diabetes, March 1, 2005; 54(3): 900 - 905. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |